Suppr超能文献

异柠檬酸脱氢酶1(IDH1)突变型胶质瘤因聚(ADP-核糖)聚合酶1(PARP1)介导的DNA修复受损而产生的化学敏感性。

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.

作者信息

Lu Yanxin, Kwintkiewicz Jakub, Liu Yang, Tech Katherine, Frady Lauren N, Su Yu-Ting, Bautista Wendy, Moon Seog In, MacDonald Jeffrey, Ewend Matthew G, Gilbert Mark R, Yang Chunzhang, Wu Jing

机构信息

Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

出版信息

Cancer Res. 2017 Apr 1;77(7):1709-1718. doi: 10.1158/0008-5472.CAN-16-2773. Epub 2017 Feb 15.

Abstract

Mutations in isocitrate dehydrogenase () are the most prevalent genetic abnormalities in lower grade gliomas. The presence of these mutations in glioma is prognostic for better clinical outcomes with longer patient survival. In the present study, we found that defects in oxidative metabolism and 2-HG production confer chemosensitization in IDH1-mutated glioma cells. In addition, temozolomide (TMZ) treatment induced greater DNA damage and apoptotic changes in mutant glioma cells. The PARP1-associated DNA repair pathway was extensively compromised in mutant cells due to decreased NAD availability. Targeting the PARP DNA repair pathway extensively sensitized IDH1-mutated glioma cells to TMZ. Our findings demonstrate a novel molecular mechanism that defines chemosensitivity in IDH-mutated gliomas. Targeting PARP-associated DNA repair may represent a novel therapeutic strategy for gliomas. .

摘要

异柠檬酸脱氢酶(IDH)突变是低级别胶质瘤中最常见的基因异常。胶质瘤中这些突变的存在预示着更好的临床结果和更长的患者生存期。在本研究中,我们发现氧化代谢缺陷和2-羟基戊二酸(2-HG)生成赋予IDH1突变的胶质瘤细胞化学敏感性。此外,替莫唑胺(TMZ)处理在突变的胶质瘤细胞中诱导了更大的DNA损伤和凋亡变化。由于烟酰胺腺嘌呤二核苷酸(NAD)可用性降低,PARP1相关的DNA修复途径在突变细胞中受到广泛损害。靶向PARP DNA修复途径使IDH1突变的胶质瘤细胞对TMZ高度敏感。我们的研究结果证明了一种定义IDH突变胶质瘤化学敏感性的新分子机制。靶向PARP相关的DNA修复可能代表一种治疗胶质瘤的新策略。

相似文献

1
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Cancer Res. 2017 Apr 1;77(7):1709-1718. doi: 10.1158/0008-5472.CAN-16-2773. Epub 2017 Feb 15.
2
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Cancer Res Treat. 2021 Apr;53(2):367-377. doi: 10.4143/crt.2020.506. Epub 2020 Oct 13.
4
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.
5
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Oncotarget. 2017 Apr 25;8(17):28865-28879. doi: 10.18632/oncotarget.15868.
6
ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Theranostics. 2020 Feb 10;10(7):3351-3365. doi: 10.7150/thno.41219. eCollection 2020.
8
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Tumour Biol. 2015 Feb;36(2):655-62. doi: 10.1007/s13277-014-2644-z. Epub 2014 Oct 5.
9
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in -Mutant Cancers and Potentiates NAD Depletion-Mediated Cytotoxicity.
Cancer Res. 2017 Aug 1;77(15):4102-4115. doi: 10.1158/0008-5472.CAN-16-2263. Epub 2017 Jun 16.
10
EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
Curr Cancer Drug Targets. 2024;24(3):328-339. doi: 10.2174/1568009623666230818151830.

引用本文的文献

2
Clinical approaches to overcome PARP inhibitor resistance.
Mol Cancer. 2025 May 30;24(1):156. doi: 10.1186/s12943-025-02355-1.
3
Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.
Future Oncol. 2025 Jul;21(16):2089-2099. doi: 10.1080/14796694.2025.2511587. Epub 2025 May 27.
7
Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations.
Drug Deliv Transl Res. 2025 Apr 21. doi: 10.1007/s13346-025-01859-z.
8
Mechanism analysis and targeted therapy of IDH gene mutation in glioma.
Am J Cancer Res. 2025 Jan 15;15(1):248-270. doi: 10.62347/NSXC2205. eCollection 2025.
9
D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming.
Nat Commun. 2025 Feb 7;16(1):1431. doi: 10.1038/s41467-025-56781-2.

本文引用的文献

1
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
Cancer Cell. 2016 Aug 8;30(2):337-348. doi: 10.1016/j.ccell.2016.05.018. Epub 2016 Jul 14.
2
Biosensor reveals multiple sources for mitochondrial NAD⁺.
Science. 2016 Jun 17;352(6292):1474-7. doi: 10.1126/science.aad5168.
3
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Cancer Cell. 2015 Dec 14;28(6):773-784. doi: 10.1016/j.ccell.2015.11.006.
4
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Cancer Res. 2015 Nov 15;75(22):4790-802. doi: 10.1158/0008-5472.CAN-14-3603. Epub 2015 Sep 11.
5
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.
Cancer Res. 2015 Aug 1;75(15):2999-3009. doi: 10.1158/0008-5472.CAN-15-0840. Epub 2015 Jun 4.
6
Mutational landscape and clonal architecture in grade II and III gliomas.
Nat Genet. 2015 May;47(5):458-68. doi: 10.1038/ng.3273. Epub 2015 Apr 13.
7
Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14217-22. doi: 10.1073/pnas.1409653111. Epub 2014 Sep 15.
8
ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion.
Cell Rep. 2014 Sep 25;8(6):1819-1831. doi: 10.1016/j.celrep.2014.08.036. Epub 2014 Sep 15.
9
Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Cancer Res. 2014 Sep 1;74(17):4836-44. doi: 10.1158/0008-5472.CAN-14-0924. Epub 2014 Jul 17.
10
Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis.
Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10209-14. doi: 10.1073/pnas.1405158111. Epub 2014 Jul 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验